ZOSTAVAX™ (Zoster Vaccine Live) Long-term Effectiveness Study (V211-024)

CompletedOBSERVATIONAL

Enrollment

1,505,647

Participants

Timeline

Start Date

May 15, 2012

Primary Completion Date

October 16, 2020

Study Completion Date

October 16, 2020

Conditions

Herpes ZosterShingles

Interventions

BIOLOGICAL

ZOSTAVAX™

ZOSTAVAX™ (Zoster Vaccine Live) administered in routine clinical conditions of use

All Listed Sponsors

collaborator

Kaiser Permanente

OTHER

lead

Merck Sharp & Dohme LLC

INDUSTRY

NCT01600079 - ZOSTAVAX™ (Zoster Vaccine Live) Long-term Effectiveness Study (V211-024) | Biotech Hunter | Biotech Hunter